Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eliquis apixaban regulatory update

Germany's Federal Joint Committee (G-BA) said its June final benefit assessment for Eliquis apixaban from Bristol-Myers and Pfizer was published in Germany's Federal Gazette. In

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE